- July 28, 2023
- Posted by: legaleseblogger
- Category: Related News
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
Insilico Medicine Expands Business Development and Licensing Team with Appointment of Michael Bayewitch, PhD
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Head of Business Development and Licensing North America. In this role, Dr. Bayewitch will lead Insilico’s BD team on the East and West Coasts and provide support for the company’s BD activities in Israel and Europe. This expansion of Dr. Bayewitch’s role is part of Insilico’s evolving BD strategy, which focuses on asset partnering and out-licensing.
Insilico Medicine currently has 31 programs across 29 targets in its pipeline, covering therapeutic areas such as fibrosis, oncology, autoimmune inflammatory, and central nervous system disorders. Since 2021, the company has announced 12 preclinical candidates that are progressing in development, with 3 of them advancing into human clinical trials. With the addition of Dr. Bayewitch to the team, Insilico aims to leverage its robust pipeline and assets into new partnerships and licensing deals.
How AI legalese decoder Can Help
The use of AI legalese decoder can greatly benefit Insilico Medicine in navigating complex legal documents and agreements related to business development and licensing. This AI-powered tool is designed to decode and interpret legal jargon, making it easier for the BD team to understand and negotiate contracts. By leveraging AI legalese decoder, Insilico can streamline the process of reviewing and finalizing agreements, saving time and reducing the risk of misunderstandings or misinterpretations. This tool can enhance the efficiency and accuracy of Insilico’s BD activities, ultimately facilitating successful asset partnering and out-licensing deals.
About Michael Bayewitch, PhD
Dr. Bayewitch brings over 22 years of experience in the pharmaceutical industry, with a focus on in/out-licensing transactions in therapeutic areas such as oncology and autoimmune diseases. Prior to joining Insilico Medicine, he held positions in various international pharmaceutical companies, including Teva Pharmaceuticals Inc., Cephalon, EOC Pharma, and Simcere Pharmaceutical Group.
About Insilico Medicine
Insilico Medicine is a clinical-stage end-to-end generative AI-driven drug discovery company. The company utilizes advanced AI platforms, including deep generative models and reinforcement learning, to connect biology, chemistry, and clinical trials analysis. These AI systems enable Insilico to discover novel targets and design molecular structures with desired properties. With a focus on cancer, fibrosis, immunity, central nervous system, and aging-related diseases, Insilico Medicine delivers innovative solutions for drug discovery and development.
To learn more about Insilico Medicine, visit www.insilico.com.
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
****** just grabbed a